Serplulimab
ATC L01FF12 · 5 markets · 5 records
GB 1 records · 1 strengths
- 100 mg/10 mLinjectionHetronifly 100mg/10ml concentrate for solution for infusion vials
SG 1 records · 1 strengths
- 100 mg/10 mLinjectionZERPIDIO (Serplulimab) Concentrate for Solution for Infusion 100mg/10ml
ES 1 records · 1 strengths
- 10 mg/1 mLinjectionHETRONIFLY
HK 1 records · 1 strengths
Records without a stated strength · 1 HETRONIFLY CONCENTRATE FOR SOLUTION FOR INFUSION 100MG/10ML
EU 1 records · 1 strengths
EU centralised authorisation (EMA) — Authorised at EU level — not a record of sale in any single country. The EU register carries no strength, dosage form or pack size.
Records without a stated strength · 1 HETRONIFLY
| Strength / form / release | GB | SG | ES | HK | EU |
|---|---|---|---|---|---|
| 100 mg/10 mL injection | Hetronifly 100mg/10ml concentrate for solution for infusion vials | ZERPIDIO (Serplulimab) Concentrate for Solution for Infusion 100mg/10ml | |||
| 10 mg/1 mL injection | HETRONIFLY | ||||
unknown | HETRONIFLY CONCENTRATE FOR SOLUTION FOR INFUSION 100MG/10ML | HETRONIFLY |
Scroll horizontally for more markets →
Each country column shows the locally registered trade names — not translations.
“not disclosed” means the source does not publish the strength — it does not mean the product has none.
Hong Kong records are name/ingredient-level only: no strength, dosage form or registration status; on the register does not prove current supply.
EU centralised authorisation (EMA) — Authorised at EU level — not a record of sale in any single country. The EU register carries no strength, dosage form or pack size.
Discontinued, withdrawn or unverified-status products are hidden by default; Hong Kong and Australia records are shown as exceptions.